<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00675987</url>
  </required_header>
  <id_info>
    <org_study_id>2007-P-000490</org_study_id>
    <nct_id>NCT00675987</nct_id>
  </id_info>
  <brief_title>A Randomized Clinical Trial To Study Losartan On Endothelial Dysfunction and Insulin Resistance In Obese Patients</brief_title>
  <official_title>Protocol Merck 318-00: A Double-Blind, Placebo-Controlled, Randomized, Parallel, Clinical Trial To Study The Effect Of Losartan Potassium On Endothelial Dysfunction And Insulin Resistance In Obese Patients With Impaired Fasting Glucose</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Brigham and Women's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purposes of this study are to find out if the study drug losartan (Cozaar) or
      placebo (&quot;sugar pill&quot;) has an effect on insulin sensitivity (how your body responds to
      insulin) and to measure the effect of the study drug losartan or placebo on how the arteries
      in your arm dilate (enlarge to carry more blood).

      We hope to learn if taking losartan changes the amount of certain proteins in the blood that
      effect blood vessel function.

      Losartan is approved by the US FDA to treat high blood pressure. It will take approximately 4
      months for you to complete this study.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2007</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Insulin Sensitivity Utilizing the Euglycemic Hyperinsulinemic Clamp</measure>
    <time_frame>baseline, 8 weeks</time_frame>
    <description>Insulin clamp derived insulin sensitivity, as insulin stimulated glucose disposal corrected for steady state insulin level.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Insulin Sensitivity Utilizing Endothelial Function as Assessed by Pulse Volume Amplitude</measure>
    <time_frame>baseline, 8 weeks</time_frame>
    <description>Endothelial function assessed as the ratio of pulse volume amplitude after compared with before a reactive hyperemia stimulus, measured by peripheral (fingertip) arterial tonometry. Reported values indicate the percentage change from Baseline in the ratio of pulse volume amplitude after compared to before the reactive hyperemia stimulus.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Urine Albumin/Creatine</measure>
    <time_frame>baseline, 8 weeks</time_frame>
    <description>Urine was obtained to assess for the presence of microalbuminuria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in hsCRP (High-sensitivity C-reactive Protein)</measure>
    <time_frame>baseline, 8 weeks</time_frame>
    <description>hsCRP (high-sensitivity C-reactive protein) is a marker of inflammation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in VCAM-1(Vascular Cell-adhesion Molecule-1)</measure>
    <time_frame>baseline, 8 weeks</time_frame>
    <description>VCAM-1 is an immunoglobulin-like adhesion molecule expressed on activated endothelial cells.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in MCP-1 (Monocyte Chemoattractant Protein-1)</measure>
    <time_frame>baseline, 8 weeks</time_frame>
    <description>MCP-1 is one of the key chemokines that regulate migration and infiltration of monocytes/macrophages.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Ox-LDL (Oxidized Low-density Lipoprotein)</measure>
    <time_frame>baseline, 8 weeks</time_frame>
    <description>ox-LDL measures protein damage due to the oxidative modification of the ApoB subunit on LDL cholesterol.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in F2-isoprostanes</measure>
    <time_frame>baseline, 8 weeks</time_frame>
    <description>F2-isoprostanes is a marker of oxidative stress.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in E-selectin</measure>
    <time_frame>baseline, 8 weeks</time_frame>
    <description>E-selectin is expressed on inflamed endothelial cells in response to treatment with inflammatory cytokines.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">53</enrollment>
  <condition>Obesity</condition>
  <condition>Hypertension</condition>
  <condition>Hyperglycemia</condition>
  <arm_group>
    <arm_group_label>Losartan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Losartan 100 mg 1 tab po QD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo 1 tab po QD</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>losartan</intervention_name>
    <description>losartan 100 mg tablets 1 tab po QD</description>
    <arm_group_label>Losartan</arm_group_label>
    <other_name>Cozaar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo control</intervention_name>
    <description>Placebo 1 po QD</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Currently taking 1 or no antihypertensive medication

          -  Male and female between 18 and 75 years of age

          -  Mean trough sitting diastolic blood pressure (SiDBP) ≥80 and &lt; 100 mm Hg

          -  Mean trough sitting systolic blood pressure (SiSBP) ≥120 and &lt;160 mm Hg

          -  Non-diabetic patients with fasting plasma glucose ≥100 mg/dL and &lt;126 mg/dL

          -  Body mass index (BMI) &gt;30 and &lt;40

          -  Waist circumference &gt;40 inches in males, &gt; 35 inches in females

          -  A patient who is of reproductive potential and agrees to remain abstinent or use
             acceptable methods of birth control (intrauterine device (IUD), diaphragm with
             spermicide, contraceptive sponge, condom, hormonal contraception, vasectomy) within
             the projected duration of the study

        Exclusion Criteria:

          -  Secondary hypertension of any etiology (renal artery stenosis, coarctation of the
             aorta or pheochromocytoma, hypertension induced by oral contraceptives)

          -  History of malignant hypertension

          -  Any clinically significant renal disease including single functioning kidney, and
             known history of anuria. Any severe renal impairment, as manifested by serum
             creatinine more than 1.5 mg/dL, or proteinuria &gt;2+ by urine dipstick

          -  Known sensitivity or intolerance to angiotensin II receptor antagonists

          -  Type I or II diabetes

          -  Inability or unwillingness to abstain from taking prohibited medications during the
             study period

          -  History of myocardial infarction (MI), percutaneous coronary intervention (PCI),
             coronary artery bypass graft (CABG), congestive heart failure (CHF), unstable angina,
             transient ischemic attack (TIA), or cerebrovascular accident (CVA)

          -  Concomitant cardiac conditions that would make it unsafe to participate in the trial
             (e.g., clinically significant atrioventricular (AV) conduction disturbance, atrial
             flutter, atrial fibrillation, potentially life-threatening ventricular arrhythmias,
             decompensated valvular disease, presence of hemodynamically significant obstructive
             valvular disease, or cardiomyopathy)

          -  History of angioedema and/or organ damage from hypertension

          -  Serum potassium &lt; 3.5 or &gt; 5.5 mEq/L

          -  Any clinically significant laboratory value which in the investigator's judgment could
             be clinically significant to the outcome of this study.

          -  History of clinically important gastrointestinal resection or malabsorption

          -  Patient with a history or current evident of any condition, therapy, lab abnormality,
             or other circumstance that might confound the results of the study, or interfere with
             the patient's participation for the full duration of the study, such that it is not in
             the best interest of the patient to participate. (Including but not limited to: recent
             or current alcoholism, drug abuse within the prior 2 years, mental or legal
             incapacitation, any disease which could reasonably be expected to be fatal or
             life-threatening, or a history of malignancy ≤ 5 years prior to signing informed
             consent.)

          -  Currently participating or has participated in a study with an investigational
             compound or device within 30 days of signing informed consent.

          -  Inability to be taken off all current antihypertensive medication and placed on
             placebo for up to 12 weeks.

          -  Unwillingness or unlikely to adhere to the study procedures, keep appointments, or is
             planning to relocate during the study.

          -  Arm circumference great than 52 cm

          -  Smokers or former smokers who have quite less than 1 year prior to Visit 1

          -  Anemia (Hemoglobin &lt; 11)

          -  Allergy to latex

          -  Deformed hands and/or fingers that would interfere with the collection of pulse volume
             amplitude measurements

          -  History of Raynaud's disease or any other vascular condition

          -  Bilateral mastectomy

          -  Aortic stenosis

          -  Patient is taking high doses of antioxidant supplements (vitamins, minerals, or other)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark A Creager, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brigham and Women's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CAVS Clinical Research Center</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA San Diego Health Care System</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92161</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami Diabetes Research Institute</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University School of Medicine</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital Cardiovascular Division</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Lukes Roosevelt Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania School of Medicine</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas SW Medical Center at Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hypertension Clinical Pharmacology Baylor Clinic</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Perlstein TS, Henry RR, Mather KJ, Rickels MR, Abate NI, Grundy SM, Mai Y, Albu JB, Marks JB, Pool JL, Creager MA. Effect of angiotensin receptor blockade on insulin sensitivity and endothelial function in abdominally obese hypertensive patients with impaired fasting glucose. Clin Sci (Lond). 2012 Feb;122(4):193-202. doi: 10.1042/CS20110284.</citation>
    <PMID>21861845</PMID>
  </results_reference>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>May 8, 2008</study_first_submitted>
  <study_first_submitted_qc>May 9, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 12, 2008</study_first_posted>
  <results_first_submitted>July 19, 2011</results_first_submitted>
  <results_first_submitted_qc>July 11, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 21, 2012</results_first_posted>
  <last_update_submitted>August 9, 2018</last_update_submitted>
  <last_update_submitted_qc>August 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brigham and Women's Hospital</investigator_affiliation>
    <investigator_full_name>Mark Alan Creager, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Impaired Fasting Glucose FPG &gt;100-&lt;126 mg/dL</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Hyperglycemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Losartan</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Losartan 100 mg 1 Tab po QD</title>
          <description>Losartan 100 mg 1 tab po QD</description>
        </group>
        <group group_id="P2">
          <title>Placebo 1 Tab po QD</title>
          <description>Placebo 1 tab po QD</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Losartan 100 mg 1 Tab po QD</title>
          <description>Losartan 100 mg 1 tab po QD</description>
        </group>
        <group group_id="B2">
          <title>Placebo 1 Tab po QD</title>
          <description>Placebo 1 tab po QD</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="26"/>
            <count group_id="B2" value="27"/>
            <count group_id="B3" value="53"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="53"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51.1" spread="10.5"/>
                    <measurement group_id="B2" value="53.8" spread="8.3"/>
                    <measurement group_id="B3" value="52.5" spread="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Insulin Sensitivity Utilizing the Euglycemic Hyperinsulinemic Clamp</title>
        <description>Insulin clamp derived insulin sensitivity, as insulin stimulated glucose disposal corrected for steady state insulin level.</description>
        <time_frame>baseline, 8 weeks</time_frame>
        <population>analysis was ITT, but limited to those with interpretable data (3 clamp studies were excluded)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo 1 tab po QD</description>
          </group>
          <group group_id="O2">
            <title>Losartan</title>
            <description>Losartan 100 mg 1 tab po QD</description>
          </group>
        </group_list>
        <measure>
          <title>Insulin Sensitivity Utilizing the Euglycemic Hyperinsulinemic Clamp</title>
          <description>Insulin clamp derived insulin sensitivity, as insulin stimulated glucose disposal corrected for steady state insulin level.</description>
          <population>analysis was ITT, but limited to those with interpretable data (3 clamp studies were excluded)</population>
          <units>mg/kg/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.3" spread="4.5"/>
                    <measurement group_id="O2" value="2.8" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Insulin Sensitivity Utilizing Endothelial Function as Assessed by Pulse Volume Amplitude</title>
        <description>Endothelial function assessed as the ratio of pulse volume amplitude after compared with before a reactive hyperemia stimulus, measured by peripheral (fingertip) arterial tonometry. Reported values indicate the percentage change from Baseline in the ratio of pulse volume amplitude after compared to before the reactive hyperemia stimulus.</description>
        <time_frame>baseline, 8 weeks</time_frame>
        <population>analysis was ITT, but limited to those with interpretable data (3 clamp studies were excluded)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo 1 tab po QD</description>
          </group>
          <group group_id="O2">
            <title>Losartan</title>
            <description>Losartan 100 mg 1 tab po QD</description>
          </group>
        </group_list>
        <measure>
          <title>Insulin Sensitivity Utilizing Endothelial Function as Assessed by Pulse Volume Amplitude</title>
          <description>Endothelial function assessed as the ratio of pulse volume amplitude after compared with before a reactive hyperemia stimulus, measured by peripheral (fingertip) arterial tonometry. Reported values indicate the percentage change from Baseline in the ratio of pulse volume amplitude after compared to before the reactive hyperemia stimulus.</description>
          <population>analysis was ITT, but limited to those with interpretable data (3 clamp studies were excluded)</population>
          <units>percentage change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.76" spread="0.7"/>
                    <measurement group_id="O2" value="2.11" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Urine Albumin/Creatine</title>
        <description>Urine was obtained to assess for the presence of microalbuminuria.</description>
        <time_frame>baseline, 8 weeks</time_frame>
        <population>27 participants were randomized to placebo, and 26 participants were randomized to Losartan, but 1 placebo participant and 1 Losartan participant did not complete the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo 1 tab po QD
Placebo control: Placebo 1 po QD</description>
          </group>
          <group group_id="O2">
            <title>Losartan</title>
            <description>Losartan 100 mg 1 tab po QD
losartan: losartan 100 mg tablets 1 tab po QD</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Urine Albumin/Creatine</title>
          <description>Urine was obtained to assess for the presence of microalbuminuria.</description>
          <population>27 participants were randomized to placebo, and 26 participants were randomized to Losartan, but 1 placebo participant and 1 Losartan participant did not complete the study.</population>
          <units>mg/mmol</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" lower_limit="-0.1" upper_limit="0.9"/>
                    <measurement group_id="O2" value="0.2" lower_limit="-0.3" upper_limit="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in hsCRP (High-sensitivity C-reactive Protein)</title>
        <description>hsCRP (high-sensitivity C-reactive protein) is a marker of inflammation</description>
        <time_frame>baseline, 8 weeks</time_frame>
        <population>27 participants were randomized to placebo, and 26 participants were randomized to Losartan, but 1 placebo participant and 1 Losartan participant did not complete the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo 1 tab po QD
Placebo control: Placebo 1 po QD</description>
          </group>
          <group group_id="O2">
            <title>Losartan</title>
            <description>Losartan 100 mg 1 tab po QD
losartan: losartan 100 mg tablets 1 tab po QD</description>
          </group>
        </group_list>
        <measure>
          <title>Change in hsCRP (High-sensitivity C-reactive Protein)</title>
          <description>hsCRP (high-sensitivity C-reactive protein) is a marker of inflammation</description>
          <population>27 participants were randomized to placebo, and 26 participants were randomized to Losartan, but 1 placebo participant and 1 Losartan participant did not complete the study.</population>
          <units>percentage change</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10" lower_limit="-32" upper_limit="20"/>
                    <measurement group_id="O2" value="-34" lower_limit="-50" upper_limit="-13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in VCAM-1(Vascular Cell-adhesion Molecule-1)</title>
        <description>VCAM-1 is an immunoglobulin-like adhesion molecule expressed on activated endothelial cells.</description>
        <time_frame>baseline, 8 weeks</time_frame>
        <population>27 participants were randomized to placebo, and 26 participants were randomized to Losartan, but 1 placebo participant and 1 Losartan participant did not complete the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo 1 tab po QD
Placebo control: Placebo 1 po QD</description>
          </group>
          <group group_id="O2">
            <title>Losartan</title>
            <description>Losartan 100 mg 1 tab po QD
losartan: losartan 100 mg tablets 1 tab po QD</description>
          </group>
        </group_list>
        <measure>
          <title>Change in VCAM-1(Vascular Cell-adhesion Molecule-1)</title>
          <description>VCAM-1 is an immunoglobulin-like adhesion molecule expressed on activated endothelial cells.</description>
          <population>27 participants were randomized to placebo, and 26 participants were randomized to Losartan, but 1 placebo participant and 1 Losartan participant did not complete the study.</population>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29" lower_limit="-20" upper_limit="79"/>
                    <measurement group_id="O2" value="-21" lower_limit="-70" upper_limit="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in MCP-1 (Monocyte Chemoattractant Protein-1)</title>
        <description>MCP-1 is one of the key chemokines that regulate migration and infiltration of monocytes/macrophages.</description>
        <time_frame>baseline, 8 weeks</time_frame>
        <population>27 participants were randomized to placebo, and 26 participants were randomized to Losartan, but 1 placebo participant and 1 Losartan participant did not complete the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo 1 tab po QD
Placebo control: Placebo 1 po QD</description>
          </group>
          <group group_id="O2">
            <title>Losartan</title>
            <description>Losartan 100 mg 1 tab po QD
losartan: losartan 100 mg tablets 1 tab po QD</description>
          </group>
        </group_list>
        <measure>
          <title>Change in MCP-1 (Monocyte Chemoattractant Protein-1)</title>
          <description>MCP-1 is one of the key chemokines that regulate migration and infiltration of monocytes/macrophages.</description>
          <population>27 participants were randomized to placebo, and 26 participants were randomized to Losartan, but 1 placebo participant and 1 Losartan participant did not complete the study.</population>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-37" lower_limit="-80" upper_limit="6.8"/>
                    <measurement group_id="O2" value="-24" lower_limit="-65" upper_limit="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Ox-LDL (Oxidized Low-density Lipoprotein)</title>
        <description>ox-LDL measures protein damage due to the oxidative modification of the ApoB subunit on LDL cholesterol.</description>
        <time_frame>baseline, 8 weeks</time_frame>
        <population>27 participants were randomized to placebo, and 26 participants were randomized to Losartan, but 1 placebo participant and 1 Losartan participant did not complete the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo 1 tab po QD
Placebo control: Placebo 1 po QD</description>
          </group>
          <group group_id="O2">
            <title>Losartan</title>
            <description>Losartan 100 mg 1 tab po QD
losartan: losartan 100 mg tablets 1 tab po QD</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Ox-LDL (Oxidized Low-density Lipoprotein)</title>
          <description>ox-LDL measures protein damage due to the oxidative modification of the ApoB subunit on LDL cholesterol.</description>
          <population>27 participants were randomized to placebo, and 26 participants were randomized to Losartan, but 1 placebo participant and 1 Losartan participant did not complete the study.</population>
          <units>units/l</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.0" lower_limit="-8.1" upper_limit="4.1"/>
                    <measurement group_id="O2" value="-5.5" lower_limit="-11.9" upper_limit="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in F2-isoprostanes</title>
        <description>F2-isoprostanes is a marker of oxidative stress.</description>
        <time_frame>baseline, 8 weeks</time_frame>
        <population>27 participants were randomized to placebo, and 26 participants were randomized to Losartan, but 1 placebo participant and 1 Losartan participant did not complete the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo 1 tab po QD
Placebo control: Placebo 1 po QD</description>
          </group>
          <group group_id="O2">
            <title>Losartan</title>
            <description>Losartan 100 mg 1 tab po QD
losartan: losartan 100 mg tablets 1 tab po QD</description>
          </group>
        </group_list>
        <measure>
          <title>Change in F2-isoprostanes</title>
          <description>F2-isoprostanes is a marker of oxidative stress.</description>
          <population>27 participants were randomized to placebo, and 26 participants were randomized to Losartan, but 1 placebo participant and 1 Losartan participant did not complete the study.</population>
          <units>ng/mg of creatinine</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" lower_limit="-0.9" upper_limit="1.6"/>
                    <measurement group_id="O2" value="0.9" lower_limit="-0.4" upper_limit="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in E-selectin</title>
        <description>E-selectin is expressed on inflamed endothelial cells in response to treatment with inflammatory cytokines.</description>
        <time_frame>baseline, 8 weeks</time_frame>
        <population>27 participants were randomized to placebo, and 26 participants were randomized to Losartan, but 1 placebo participant and 1 Losartan participant did not complete the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo 1 tab po QD
Placebo control: Placebo 1 po QD</description>
          </group>
          <group group_id="O2">
            <title>Losartan</title>
            <description>Losartan 100 mg 1 tab po QD
losartan: losartan 100 mg tablets 1 tab po QD</description>
          </group>
        </group_list>
        <measure>
          <title>Change in E-selectin</title>
          <description>E-selectin is expressed on inflamed endothelial cells in response to treatment with inflammatory cytokines.</description>
          <population>27 participants were randomized to placebo, and 26 participants were randomized to Losartan, but 1 placebo participant and 1 Losartan participant did not complete the study.</population>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.6" lower_limit="-4.5" upper_limit="1.3"/>
                    <measurement group_id="O2" value="-0.6" lower_limit="-3.5" upper_limit="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Losartan</title>
          <description>Losartan 100 mg 1 tab po QD</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo 1 tab po QD</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Mark A. Creager, MD</name_or_title>
      <organization>Brigham and Women's Hospital</organization>
      <phone>617-732-5267</phone>
      <email>mcreager@partners.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

